bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.
21.07.2023bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.
bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.
21.07.2023bit.bio's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.
An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.
17.07.2023bit.bio is partnering with the iGEM student competition, aimed at advancing the field of synthetic biology.
07.07.2023Our VP of R&D Manos Metzakopian writes in Innovations in Pharmaceutical Technology about novel technologies that enable researcher...
17.04.2023Device that could restore limb function to amputees and others who have lost the use of their arms or legs uses opti-ox reprogramm...
23.03.2023Our CEO was interviewed in this piece about the barriers and opportunities for scaling companies in the UK.
14.03.2023Featured in Technology Dispatch, bit.bio SVP of Technical Operations & Cell Manufacturing, Kathryn Golden, shares her insights int...
10.03.2023bit.bio received a bronze award for its participation in the Green Impact awards for sustainability.
26.09.2022bit.bio is supporting the iGEM team from University of Cambridge in the iGEM synbio competition.
22.08.2022